Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer
- Citation:
- J Clin Oncol vol 35 (15 suppl) abstr 502
- Meeting Instance:
- ASCO 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3331
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- Alvaro Moreno-Aspitia Eileen Holmes Christian Jackisch Evandro de Azambuja Frances Boyle David W. Hillman Larissa Korde Debora Fumagalli Miguel Izquierdo Ann McCullough Antonio C. Wolff Kathleen Pritchard Michael Untch Istvan Lang Binghe Xu Ian Smith Carlos H. Barrios Rich Gelber Jose Baselga Martine Piccart-Gebhart
- Networks:
- LAPS-MD017, LAPS-MN026, LAPS-NY016
- Study
- NCCTG-N063D
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: